NCT02319837 2025-07-08Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)PfizerPhase 3 Active not recruiting1,068 enrolled 20 charts 1 FDA